Skinvisible

Skinvisible ROE

The Return on Equity (ROE) of Skinvisible (SKVI) as of Oct 21, 2026 is 10.37 %. In the previous year, Return on Equity (ROE) was 6.13 % — a change of 69.06% (higher).

ROE

10.37 %

YoY

69.06%

Last updated:

In 2025, Skinvisible's return on equity (ROE) was 10.37 %, a 69.06% increase from the 6.13 % ROE in the previous year.

The Skinvisible ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-3.36 USD
Jan 1, 2019
56.60 USD
Jan 1, 2020
32.50 USD
Jan 1, 2021
19.81 USD
Jan 1, 2022
18.45 USD
Jan 1, 2023
26.40 USD
Jan 1, 2024
6.13 USD
Jan 1, 2025
10.37 USD
The Skinvisible ROE history
YEARROEYoY
10.37 %+69.06%
6.13 %-76.77%
26.40 %+43.15%
18.45 %-6.88%
19.81 %-39.04%
32.50 %-42.59%
56.60 %-1,787.05%
-3.36 %-112.41%
27.03 %-19.51%
33.58 %-4.48%
35.15 %-20.61%
44.28 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Skinvisible Stock analysis

What does Skinvisible do? Skinvisible Inc develops and patents the Invisicare polymer delivery system, which enhances the delivery of active ingredients in topical skin care products. The company has formulated over forty topical skin products using Invisicare, with Pivotal being the patented technology that enables extended duration of active ingredients on the skin. Invisicare specifically carries water-insoluble and certain cationic active ingredients in water-based products without alcohol, silicones, waxes, or organic solvents. The firm's revenue comes from licensing the Invisicare technology to partners who develop and sell skin care products incorporating this delivery system. Skinvisible Inc's primary customers are pharmaceutical and cosmetic companies seeking to improve the efficacy of their topical skin care formulations. These companies purchase the Invisicare technology to integrate into their own product lines, leveraging the extended delivery duration and compatibility with water-based formulations. The company does not sell end-user products but focuses on technology licensing for partners who manufacture and market the final skin care products. The business model relies on the patent protection of Invisicare, which allows Skinvisible to generate revenue through licensing agreements. Partners pay for the right to use the technology in their products, with the company's focus on developing and protecting the polymer delivery system as its core asset. The firm's product portfolio includes over forty topical skin products developed using Invisicare, but these are not sold directly by Skinvisible Inc. Skinvisible is one of the most popular companies on Eulerpool.

ROE Details

Decoding Skinvisible's Return on Equity (ROE)

Skinvisible's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Skinvisible's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Skinvisible's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Skinvisible’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Skinvisible stock

Return on Equity (ROE) of Skinvisible is 10.37 % in 2025.

Return on Equity (ROE) of Skinvisible changed from 6.13 % to 10.37 %, representing a 69.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Skinvisible since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Skinvisible with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Skinvisible

All Key Metrics — Skinvisible